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Dravet syndrome (DS) is a genetic encephalopathy that is characterized by severe
seizures and prominent co-morbidities (e.g., physical, intellectual disabilities). More
than 85% of the DS patients carry an SCN1A mutation (sodium channel, voltage
gated, type I alpha subunit). Although numerous anti-epileptic drugs have entered the
market since 1990, these drugs often fail to adequately control seizures in DS patients.
Nonetheless, current clinical data shows significant seizure reduction in DS patients
treated with the serotonergic (5-hydroxytryptamine, 5-HT) drug fenfluramine (FA). Recent
preclinical research confirmed the anti-epileptiform activity of FA in homozygous scn1a
mutant zebrafish larvae that mimic DS well. Here we explored the anti-epileptiform
mechanisms of FA by investigating whether selective agonists/antagonists of specific
receptor subtypes were able to counteract the FA-induced inhibition of seizures and
abnormal brain discharges observed in the scn1a mutants. We show that antagonists
of 5-HT1D and 5-HT2C receptor subtypes were able to do so (LY 310762 and SB
242084, respectively), but notably, a 5-HT2A-antagonist (ketanserin) was not. In addition,
exploring further the mechanism of action of FA beyond its serotonergic profile, we found
that the anti-epileptiform brain activity of FA was significantly abolished when it was
administered in combination with a σ1-agonist (PRE 084). Our study therefore provides
the first evidence of an involvement of the σ1 receptor in the mechanism of FA. We further
show that the level of some neurotransmitters [i.e., dopamine and noradrenaline (NAD)]
in head homogenates was altered after FA treatment, whereas γ-aminobutyric acid
(GABA) and glutamate levels were not. Of interest, NAD-decreasing drugs have been
employed successfully in the treatment of neurological diseases; including epilepsy and
this effect could contribute to the therapeutic effect of the compound. In summary, we
hypothesize that the anti-epileptiform activity of FA not only originates from its 5-HT1D-
and 5-HT2C-agonism, but likely also from its ability to block σ1 receptors. These findings
will help in better understanding the pharmacological profile of compounds that is
critical for their applicability in the treatment of DS and possibly also other drug-resistant
epilepsies.
Keywords: epilepsy, Dravet syndrome, Zebrafish, pharmacological modulation, GABA, glutamate, monoamines,
sigma
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INTRODUCTION
Epilepsy is a severe neurological disease affecting 65 million
people worldwide (Moshé et al., 2015). It is marked by abnormal
electrical activity in the brain and is associated with precipitous
recurrent episodes of involuntary movements and/or loss of
consciousness. Various epilepsy syndromes have been described
with different etiologies (e.g., genetic, structural, metabolic,
infectious or unknown cause). In general, multiple genes and/or
environmental factors are implicated in the pathogenesis of
epilepsy but also monogenic epilepsy syndromes exist (Williams
and Battaglia, 2013). Of interest, these monogenic pathologies
can be mimicked rather easily by genetic animal models (Dinday
and Baraban, 2015; Sourbron et al., 2016).
A de novo mutation in the SCN1A gene (sodium channel,
voltage gated, type I alpha subunit) has been proven to be the
cause in more than 85% of the DS patients (Mastrangelo and
Leuzzi, 2012). This monogenic epilepsy syndrome, which was
also known as severe myoclonic epilepsy of infancy (SMEI),
is an uncommon but severe encephalopathy that starts in the
first year of life (Dravet, 2011). Moreover it is one of the most
drug-resistant epilepsy syndromes, highlighting the need for new
innovative drugs with novel mechanisms of action.
Even though new AEDs have been developed over the
past two decades, the treatment of drug-resistant epilepsy
has not improved significantly (Ventola, 2014). Notably, some
interesting progress has been made in the understanding of
the mechanisms underlying epilepsy, revealing novel targets for
future AEDs (Löscher et al., 2013). For instance, current evidence
underscores the role of SER (5-HT) in epilepsy and it has
been suggested that serotonergic drugs have great potential in
the treatment of various epilepsy conditions (Gharedaghi et al.,
2014).
One interesting example of a successful epilepsy therapy based
on serotonergic modulation relates to the use of fenfluramine
(FA) as an add-on drug in a small clinical trial of DS patients
(Ceulemans et al., 2012). FA is a potent SER releaser and
also directly acts on multiple 5-HT receptor subtypes, 14 of
which have been described in humans. Prospective data also
demonstrated the efficacy and safety of FA in treating DS patients
(Schoonjans et al., 2015), which led to the initiation of clinical
Phase III studies early in 20161.
Zebrafish (Danio rerio) are increasingly used in neurological
research (Best and Alderton, 2008) and the high genetic
homology between ZF and human (ca. 70%) makes them an
attractive model to study genetic diseases (Howe et al., 2013).
Abbreviations: 5-HT, 5-hydroxytryptamine (serotonin); 5-HTP, 5-Hydroxy-
tryptophan; aCSF, artificial cerebrospinal fluid; AED, anti-epileptic drug;
cLogP, calculated LogP; DMSO, dimethylsulfoxide; DOP, dopamine; dpf, days
post fertilization; DS, Dravet syndrome; EEG, electroencephalogram; GABA,
γ-aminobutyric acid; GLUT, glutamate; lardist, distance in large movements
(cm); LFP, local field potential; ms, milliseconds; MTC, maximum tolerable
concentration; mV, millivolt; NAD, noradrenaline; Nav1.1, sodium channel protein
type 1 subunit alpha isoform 1; Nav1.5, sodium channel protein type 1 subunit
alpha isoform 5; NMDA, N-methyl-D-aspartate; SCN1A, sodium channel, voltage
gated, type I alpha subunit (human); scn1Lab, sodium channel, voltage-gated, type I
like, alpha b (zebrafish); SER, serotonin; VHC, vehicle; WT, wild type; ZF, zebrafish.
1http://Zogenix.com
More than 80% of the known epilepsy-related genes are found
in the ZF genome and different groups were able to generate
ZF epilepsy models by specific gene manipulation, recapitulating
the main characteristics of the human disease, e.g., fever-sensitive
myoclonic epilepsy (CHD2 and SCN1A) (Suls et al., 2013; Zhang
et al., 2015) and fever-associated epilepsy (STX1B) (Schubert
et al., 2014). In addition, the phenotype of homozygous scn1Lab
mutant ZF larvae (herein referred to as scn1a mutant larvae)
has been studied and mirrors the clinical features of DS well.
Significantly, these mutants did not respond to currently available
AEDs and only valproic acid and FA were effective in treating
seizures, as seen in DS patients (Dinday and Baraban, 2015;
Sourbron et al., 2016).
Our pharmacological investigations using scn1a mutant larvae
showed that stimulation of the 5-HT2B receptor (by BW 723C86,
a selective 5-HT2B-agonist) did not generate an anti-epileptiform
effect whereas the application of selective 5-HT1D- (GR 46611),
5-HT2A- (TCB 2) or 5-HT2C- (lorcaserin) agonists resulted in a
significant decrease of epileptiform locomotor and brain activity
(Sourbron et al., 2016). However, direct evidence that these 5-
HT receptor subtypes are implicated in the pharmacological
activity of FA is presently lacking. Moreover, in vitro assays
interrogating potential targets suggested beta2-adrenergic- (β2)
and sigma- (σ) antagonism as possibly involved in the mechanism
of FA (Parthena et al., 2016). These receptors have relatively high
protein similarity compared to their human counterparts, which
amounts to 68.2 and 79.5 % for the β2 receptor and σ1 receptor,
respectively [as calculated by EMBOSS stretcher, (Rice et al.,
2000)]. In addition, they show a pronounced expression in the
ZF brain (comparable to the human proteins) (Wang et al., 2009;
Moritz et al., 2015). Structural data regarding the σ2 receptor
subtype are more ill-defined, even though selective compounds
with high affinity for the binding site are available (Rhoades et al.,
2014).
In this study, the mechanistic profile of FA was explored
in scn1a mutant larvae by using subtype selective agonists
and antagonists of serotonergic, beta2-adrenergic- and sigma
receptors. We demonstrate that the anti-epileptiform activity
of FA originates both from its agonistic action at 5-HT1D and
5-HT2C receptors and its antagonistic action at σ1 receptors.
Moreover, we found a significant decrease of certain monoamines
in the head homogenates of ZF larvae after FA treatment.
The results obtained allowed us to put forward a mechanistic
hypothesis regarding the clinical efficacy of FA in the treatment
of DS.
MATERIALS AND METHODS
Compounds and Their Maximum
Tolerable Concentration (MTC)
Compounds were purchased from Tocris Bioscience, except
for the 5-HT2A-antagonist, ketanserin (Sigma-Aldrich) and
(±)FA that was a gift from Prof. Berten Ceulemans (Child
Neurology, University Hospital Antwerp, Belgium). Agonists
and antagonists were selected by their high and selective
affinity for a specific receptor (Tables 1, 2). In addition, all
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TABLE 1 | Compounds with selective agonistic or antagonistic activity at the beta2-adrenergic (β2) or the sigma receptors (σ1 and σ2).
Receptor Full name MTC (µM) MW (g/mol) cLogP Ki (nM) Ki (other receptor
subtypes) (nM)
Reference
AGONIST
σ1-Agonist PRE 084 6.25 317.43 3.63 2.2 13091.0 (σ2) Nakazato et al., 1999
ANTAGONIST
β2-Antagonist ICI 118551 50.00 277.41 2.93 1.2 120.0 (β1) Wenzel et al., 2009
257.0 (β3)
σ1-Antagonist NE 100 6.25 327.47 4.35 1.0 212.0 (σ2) Nakazato et al., 1999
σ2-Antagonist SM 21 6.25 453.92 4.20 145.0 1050.0 (σ1) Matsumoto et al., 2007
TABLE 2 | Compounds with selective agonistic or antagonistic activity at specific SER (5-HT) receptor subtypes.
5-HT receptor
subtype
Full name MTC (µM) MW (g/mol) cLogP Ki (nM) Ki (other 5-HT receptor
subtype) (nM)
Reference
AGONIST
1D-Agonist PNU 109291 25.00 409.52 2.99 0.9 1700.0 (2A) Choi et al., 2008
1090.0 (1A)
2A-Agonist NBOH-2C-CN 1.25 312.37 2.96 1.3 132.0 (2C) Hansen et al., 2014
2C-Agonist Ro 600175 1.25 226.68 1.21 1.0 31.6 (2A) Tian et al., 2015
3981.1 (1A)
ANTAGONIST
1D-Antagonist LY 310762 2.50 435.44 4.44 249.0 – García-Pedraza et al., 2013
2A-Antagonist Ketanserin 0.63 372.89 3.86 0.8 21.6 (2C) Watry and Lu, 2013
28.7 (2A)
2B-Antagonist SB 204741 6.25 467.78 4.59 1.0 100.0 (2B) Watry and Lu, 2013
158.0 (2A)
2C-Antagonist SB 242084 0.31 365.86 2.37 12.0 – Watry and Lu, 2013
compounds have a cLogP value higher than one (cLogP > 1.0)
ensuring a good bioavailability in ZF larvae (Milan, 2003; García-
Pedraza et al., 2013; Watry and Lu, 2013) (Tables 1, 2). These
LogP values were calculated by an interactive calculator after
conversion of the chemical names to SMILES (cLogP range
between 1.21 and 4.59). Compounds were dissolved in DMSO
(99.9% spectroscopy grade, Acros Organics) (stock solution), and
immediately before use diluted in embryo medium to achieve a
final DMSO concentration of 0.1% w/v that also served as VHC
control.
Before performing pharmacological experiments, the MTC of
each compound was determined. Six dpf WT scn1Lab+/+ ZF
larvae (hereinafter referred to as WT larvae) were incubated
in a 96-well plate, one larva per well (tissue culture plate,
flat bottom, FALCON R©, USA), with different concentrations
of compound or VHC at 28◦C on a 14/10 h light/dark cycle
(medium was replenished daily). Each larva was checked under
the microscope during a period of 48 h for the following
signs of toxicity: decreased or no touch response upon a light
touch of the tail, loss of posture, body abnormalities, edema,
anomalies in heart rate or circulation and death. The MTC was
determined using 12 WT ZF larvae (6 dpf) and defined as the
highest concentration at which none of these larvae showed
signs of toxicity within 48 h of exposure. Compounds were
used at their MTC (Tables 1, 2), whereas FA was used at a final
concentration of 25 µM as described before (Sourbron et al.,
2016).
Zebrafish Research
Zebrafish Maintenance and Experimental Set-up
ZF (Danio rerio) heterozygous for the scn1Lab mutation
(scn1Lab+/−), backcrossed with Tupfel longfin WT (WT
scn1Lab+/+), were a generous gift of Dr. H. Baier (Freiburg,
Germany). The adult ZF were kept at 28.0◦C, on a 14/10 h
light/dark cycle under standard aquaculture conditions.
Fertilized eggs were collected via natural spawning. Genotyping
of these ZF adults and embryos was performed as described
previously (Sourbron et al., 2016). The embryos and larvae
were kept in petridishes in embryo medium containing 1.5 mM
HEPES, pH 7.6, 17.4 mM NaCl, 0.21 mM KCl, 0.12 mM MgSO4
and 0.18 mM Ca(NO3)2 in an incubator at 28.0◦C, likewise on
a 14/10 h light/dark cycle. Scn1a mutant larvae were selected
by their darker appearance, lack of a swim bladder and slight
curvature of the body (Schoonheim et al., 2010).
All ZF experiments were approved by the Ethics Committee
of the University of Leuven (Ethische Commissie van
de KU Leuven, approval number 154/2015) and by the
Belgian Federal Department of Public Health, Food Safety
& Environment (Federale Overheidsdienst Volksgezondheid,
Veiligheid van de Voedselketen en Leefmileu, approval number
LA1210199).
Locomotor Behavior
Scn1a mutant larvae and WT larvae were arrayed in a 96-
well plate (one larva per well) and treated at 6 dpf with
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VHC, compound or co-treatment of compounds for a 22 h
period as performed previously (Sourbron et al., 2016). The co-
treatment of FA and subtype selective 5-HT-antagonists and/or
the σ1-agonist was performed to investigate the mechanism
of action of FA. After incubation at 28◦C on a 14/10 h
light/dark cycle and 30 min chamber habituation 7 dpf larvae
were placed in an automated tracking device (ZebraBoxTM
apparatus; Viewpoint, Lyon, France) and their locomotor
behavior was evaluated during 10 min under dark conditions,
as described before (Sourbron et al., 2016). Locomotor activity
was quantified by the lardist parameter (total distance in
large movements) and plotted in cm (ZebraLabTM software,
Viewpoint, Lyon, France). Data were collected and pooled
together from two or three independent experiments with
at least eight larvae per treatment condition. The locomotor
data were analyzed by normalizing the locomotor activity
of treated ZF larvae against age-matched VHC-treated larvae
(method A), and by calculating the percentage of scn1a
mutant larvae with epileptiform activity below or above a
70% threshold value using the cumulative locomotor activity
during 10 min of each larva separately (method B). Method
A has been described previously (Sourbron et al., 2016)
and is performed for both scn1a mutant larvae and WT
larvae. The threshold value used in method B is based
on sensitivity analyses with different cut-off values in ‘10%-
steps’; i.e., 10, 20, 30, 40, 50, 60, 70, 80, and 90% of the
average cumulative locomotor activity during 10 min of VHC-
treated scn1a mutant larvae per experiment (data available in
Supplementary Tables S1–S5).
Forebrain Local Field Potential Recordings
The epileptiform brain activity was measured by non-invasive
surface recordings from the skin above the forebrain (Zdebik
et al., 2013). Scn1a mutant and WT larvae were treated on
6 dpf as described above [see Locomotor Behavior (Single and
Combined)] and recordings were performed at 7 dpf. ZF larvae
were immobilized by 2% low-melting-point agarose (Invitrogen)
(no paralytic was used).
The recording electrodes were made of borosilicate glass with
microfilament (GC150TF-7.5, Harvard Apparatus, UK), pulled
with DMZ Universal Puller (Zeitz, Germany) to an opening
15–20 microns, and filled with aCSF made from: 124 mM
NaCl, 2 mM KCl, 2 mM MgSO4, 2 mM CaCl2, 1.25 mM
KH2PO4, 26 mM NaHCO3 and 10 mM glucose. The differential
signal was amplified 10,000 times using DAGAN 2400 amplifier
(Minneapolis, MN, USA), band pass filtered at 0.3–300.0 Hz
and digitized at 2.0 kHz via a PCI-6251 interface (National
Instruments, UK) using WindEDR (John Dempster, University
of Strathclyde, UK). Single recordings were performed for
10 min and epileptiform activity was quantified according to the
duration of spiking paroxysms as described before (Sourbron
et al., 2016). Electrograms were analyzed with Clampfit 10.2
software (Molecular devices corporation, USA). Spontaneous
epileptiform activity was defined as events in which the amplitude
exceeded three times the baseline and lasted longer than 50 ms.
At least 10 (up to 50) ZF larvae were used per experimental
condition.
Neurotransmitter Determination
The heads of 7 dpf ZF larvae were used to quantify the amount
of the neurotransmitters 5-HT, NAD, DOP, GABA and GLUT.
Both scn1a mutant larvae and WT larvae were treated with either
VHC or FA (n = 48 for both treatment arms, leading to a total
of 192 larvae). Six heads per tube were homogenized and data
acquisition was carried out as described before (Sourbron et al.,
2016). Thereafter, the amount of neurotransmitter (in nmol) was
determined and expressed as nmol neurotransmitter per mass
head homogenate (mg).
Statistical Analysis
GraphPad Prism 5 software (GraphPad Software, Inc.) was used
for statistical analyses.
The locomotor activity was analyzed by the methods described
above [see Locomotor Behavior (Single and Combined)]. The
results obtained with method A were analyzed by One-way
ANOVA and subsequent Dunnett’s multiple comparison tests.
The results obtained with method B were performed for
the individual experiments by contingency tables, followed by
Fisher’s exact tests.
Electrographic brain activity was analyzed by a Student’s t-test
[if data passed the normality test (D’Agostino & Pearson omnibus
normality test)]. Mann–Whitney U tests were used if the data
did not pass the normality test, as described before (Sourbron
et al., 2016). To determine if the genotype (scn1a mutant vs.
WT) and/or FA treatment affected the neurotransmitter content,
data were analyzed by a two-way ANOVA for genotype and FA
treatment as the inter-subject factors. Regarding the analyses of
single vs. triple experiments [whether or not combined with FA;
see Anti-epileptiform Activity Induced by Sigma1-Antagonism
and 5-HT1D&2C-Agonism (Triple Treatment) and Counteraction
of FA’s Anti-epileptiform Activity by Sigma1-Agonism and 5-
HT1D&2C-Agonism (Triple Treatment), respectively] Mann–
Whitney U tests were applied because the data did not pass the
normality test.
For all analyses, differences between a treatment group and the
equivalent control groups were considered statistically significant
if the p-value was below 0.05 (p < 0.05).
RESULTS
To explore the anti-epileptiform mechanism(s) of FA, we used an
experimental workflow that is depicted in Figure 1.
First, we selected compounds with specific agonistic or
antagonistic activity at distinct receptor subtypes (i.e., 5-HT1D,
5-HT2A, 5-HT2C receptors, and β2, σ1, σ2 receptors, respectively)
and studied their effects on the locomotor and brain activity of
scn1a mutant larvae.
The locomotor data were analyzed by normalizing the
locomotor activity of treated ZF larvae against age-matched
VHC-treated larvae (method A), and by calculating the
percentage of scn1a mutant larvae with epileptiform activity
below or above a 70% threshold value (method B). Method A was
used to evaluate the results of both scn1a mutant larvae and WT
larvae and has the advantage to demonstrate non-specific effects,
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FIGURE 1 | Experimental workflow. Selection of compounds based on hypothesized mechanisms of FA: stimulation (agonist, left side) or inhibition (antagonist,
right side) of specific receptors. Light gray boxes show single treatment and dark gray boxes represent combinatorial treatment with FA.
e.g., a decrease in both mutant and WT larvae by sedative effects.
Method B was applied to the data of the scn1a mutant larvae
and has the advantage to account for the inherent variability of
locomotor assays (i.e., different larvae at different days) since each
larva is analyzed separately for each individual experiment.
In case of a significant decrease of epileptiform activity
for a specific agonist/antagonist [as shown by at least one
method of locomotor analysis (A and/or B) and confirmed by
forebrain LFP recordings], we continued by treating larvae in
separate experiments with a combination of FA and a compound
(combinatorial treatment) with a counteractive profile of the
agonist/antagonist previously used (in other words: in case
of an active agonist, we combined FA with an antagonist
and vice versa). Thereafter, we also tested the activity of the
agonist/antagonist used in the combinatorial treatment as a
single compound (control experiment). Finally, we performed
triple treatment experiments to examine additional effects
when combining all anti-epileptiform compounds. Similarly, we
explored FA’s pharmacological profile by combining FA with
triple treatment of compounds with the counteractive profile of
the agonists/antagonists previously used.
Anti-epileptiform Activity Induced by
Sigma1-Antagonism,
5-HT1D&2C-Agonism
Blocking the β2-adrenergic receptor (by ICI 118551) or the
σ1 receptor (by NE 100) resulted in a significant decrease of
epileptiform locomotor activity of the scn1a mutant larvae, as
identified by one of the two methods assessing locomotor activity
(i.e., method A and method B, respectively) (Figures 2A,B).
The β2-adrenergic receptor antagonist, however, also reduced
the locomotor activity of WT larvae, whereas the σ1-antagonist
did not (Figure 2A1). Subsequently, treated scn1a mutant
larvae were subjected to brain activity recordings, showing
that only the σ1-antagonist (NE 100) was able to significantly
reduce epileptiform brain activity (Figures 3A,B). Representative
traces of brain activity during 5 min recordings are depicted
in Figure 3C. σ2-antagonism (by SM 21) did not decrease
epileptiform locomotor or brain activity in scn1a mutant larvae
but lowered the locomotor activity of WT larvae (Figures 2, 3).
Previous work showed evidence for a role of 5-HT1D, 5-
HT2A, and 5-HT2C receptors in seizure modulation (Sourbron
et al., 2016). Here we reconfirmed the anti-epileptiform effect
of a distinct set of 5-HT-agonists (Figures 2A,B and Table 1).
Agonism at the 5-HT1D (by PNU 109291) and 5-HT2A receptor
(by NBOH-2C-CN) also decreased epileptiform brain activity
of scn1a mutant larvae (Figures 3A,B) and did not affect
the locomotor activity of WT larvae (Figure 2A1). Similarly,
the 5-HT2C-agonist (Ro 600175) decreased locomotor activity
of scn1a mutant but also of the WT larvae (Figure 2A1).
However, consecutive brain recordings proved the selective anti-
epileptiform activity of this compound in scn1a mutant larvae
(Figures 3A,B).
Anti-epileptiform Activity of FA and the
Counteraction by Sigma1-Agonism or
5-HT1D&2C-Antagonism (Combinatorial
Treatment)
In order to explore the mechanisms of action of FA, we combined
FA with the σ1-agonist (PRE 084) or 5-HT subtype selective
antagonists (Figure 1 and Table 2). First, we reconfirmed the
anti-epileptiform activity of FA in both assays (locomotor and
brain recordings) (Figures 4, 5) as shown before (Dinday
and Baraban, 2015; Sourbron et al., 2016). The σ1-agonist
was unable to counteract the anti-epileptiform activity of
FA in the locomotor assay (Figures 4A,B), although brain
recordings revealed a statistically significant counteraction
(Figures 5A,B). Treatment with the 5-HT1D-antagonist (LY
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FIGURE 2 | Activity profile of the selective beta2-antagonist (β2), sigma1-antagonist (σ1), sigma2-antagonist (σ2), subtype selective 5-HT-agonists (1D,
2A, 2C) and triple treatment with anti-epileptiform compounds [σ1-antagonist and subtype selective 5-HT-agonists (1D and 2C)] (locomotor
behavioral assays). Locomotor activity was normalized against VHC-treated scn1a mutant larvae and displayed as a percentage ± SD. (A1) Normalized locomotor
activity of treated scn1a mutant larvae (−/−). (A2) Normalized locomotor activity of treated WT larvae (+/+). (B) Percentage of scn1a mutant larvae with epileptiform
activity below (white area) or above the threshold value (black area). Treatment with the selective β2-antagonist, σ1-antagonist, the subtype selective 5-HT-agonists
(1D, 2A, 2C) and triple treatment with anti-epileptiform compounds [σ1-antagonist and subtype selective 5-HT-agonists (1D and 2C)] induced anti-epileptiform
locomotor activity. A statistical difference is indicated by: ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001 vs. VHC-treated controls. n = 16–30 ZF larvae for all experimental
conditions.
FIGURE 3 | Activity profile of the selective beta2-antagonist (β2), sigma1-antagonist (σ1), sigma2-antagonist (σ2), subtype selective 5-HT-agonists (1D,
2A, 2C) and triple treatment with anti-epileptiform compounds [σ1-antagonist and subtype selective 5-HT-agonists (1D and 2C)] (forebrain LFP
recordings). Quantification of brain recordings of VHC-treated WT larvae [VHC(+/+), n = 42], VHC-treated scn1a mutant larvae [VHC(−/−), n = 41] and
compound-treated scn1a mutant larvae [compound(−/−)]. (A) Frequency of epileptiform events during 10 min recording. (B) Mean cumulative duration of
epileptiform events during 10 min recording. Treatment with the selective β2-antagonist (n = 19) or the σ2-antagonist (n = 14) did not affect epileptiform brain activity
in scn1a mutant larvae. In contrast, the σ1-antagonist (n = 20), 5-HT1D-agonist (n = 10), 5-HT2A-agonist (n = 10), the 5-HT2C-agonist (n = 14) and triple treatment
with anti-epileptiform compounds [σ1-antagonist and subtype selective 5-HT-agonists (1D and 2C); n = 11] significantly reduced the frequency and the mean
cumulative duration of epileptiform brain activity in scn1a mutant larvae. A statistical difference is indicated by: ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001 vs.
VHC-treated scn1a mutant larvae. (C) Visualization of representative electrograms of 7 dpf ZF larvae: VHC-treated WT larva [VHC (+/+)], VHC-treated scn1a mutant
larva [VHC (−/−)]; β2-antagonist-treated scn1a mutant larva [β2-antagonist (−/−)]; triple treatment of scn1a mutant larva with anti-epileptiform compounds
[σ1-antagonist+5-HT1D&2C-agonists (−/−)]; scale bars: 1 mV, 30 s.
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FIGURE 4 | Activity profile of FA [single treatment with FA and combinatorial treatment of FA with the sigma1-agonist (σ1) or subtype selective
5-HT-antagonists (1D, 2A, 2C, 2B) or triple treatment of epileptiform compounds [σ1-agonist and subtype selective 5-HT-antagonists (1D and 2C)]
(locomotor behavioral assays)]. Locomotor activity was normalized against VHC-treated scn1a mutant larvae (−/−) and displayed as a percentage ± SD. (A1)
Normalized locomotor activity of treated scn1a mutant larvae (−/−). (A2) Normalized locomotor activity of treated WT larvae (+/+). (B) Percentage of scn1a mutant
larvae with epileptiform activity below (white area) or above the threshold value (black area). Single treatment with FA induced anti-epileptiform locomotor activity (FA),
which was counteracted by combinatorial treatment with the 5-HT1D-antagonist or the 5-HT2C-antagonist or triple treatment of epileptiform compounds [σ1-agonist
and subtype selective 5-HT-antagonists (1D and 2C)]. A statistical difference is indicated by: ∗p < 0.05 and ∗∗∗p < 0.001 vs. VHC-treated controls (or FA-treated
larvae). n = 16–30 ZF larvae for all experimental conditions.
310762) or the 5-HT2C-antagonist (SB 242084) significantly
counteracted the decrease in locomotor activity as elicited by
FA in scn1a mutant larvae (Figures 4A,B). This was not the
case for the 5-HT2A-antagonist (ketanserin). The locomotor
behavior was not significantly altered in age-matched WT
larvae by combinatorial treatments (Figure 4A2), pointing
to a selective effect on scn1a mutant larvae. Interestingly,
quantification of the corresponding electrograms confirmed
the significant counteraction of the 5-HT1D-antagonist and 5-
HT2C-antagonist (Figures 5A,B). Representative traces of brain
activity during 5 min recording are depicted in Figure 5C.
Finally, we performed experiments with a selective 5-HT2B-
antagonist (SB 204741, negative control). This antagonist was
unable to counteract the anti-epileptiform activity of FA in
the locomotor (Figures 4A,B) and the brain recording assays
(Figures 5A,B).
No Anti-epileptiform Activity of
Sigma1-Agonism or 5-HT-Antagonism
Subsequently, we performed single treatment experiments to
investigate whether the compounds, used in combinatorial
treatment with FA [see Anti-epileptiform Activity of FA and the
Counteraction by Sigma1-Agonism or 5-HT1D&2C-Antagonism
(Combinatorial Treatment)], affected the locomotor activity of
ZF larvae in the absence of FA (Figure 6). Treatment with
the σ1-agonist did not significantly influence the locomotor
activity of ZF larvae, although a slight statistically insignificant
increase in the epileptiform behavior of scn1a mutant larvae
was present (p > 0.05, Figure 6A). The pharmacological
inhibition of the 5-HT1D, 5-HT2A, and the 5-HT2C receptor
did not alter epileptiform locomotor activity in scn1a mutant
larvae (Figures 6A,B). The 5-HT1D-antagonist and the 5-
HT2B-antagonist significantly affected locomotor activity of age-
matched WT larvae (Figure 6A1).
Anti-epileptiform Activity Induced by
Sigma1-Antagonism and
5-HT1D&2C-Agonism (Triple Treatment)
Single treatment (σ1-antagonist, 5-HT1D- or 5-HT2C-agonist)
decreased the abnormal (epileptiform) locomotor activity
(range 17–34% decrease compared to VHC; Figure 2A1).
Triple treatment (combination of the aforementioned three
compounds) decreased the epileptiform locomotor activity to a
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FIGURE 5 | Activity profile of FA [single treatment with FA and combinatorial treatment of FA with the sigma1-agonist (σ1) or subtype selective
5-HT-antagonists (1D, 2A, 2C, 2B) or triple treatment of epileptiform compounds [σ1-agonist and subtype selective 5-HT-antagonists (1D and 2C)]
(forebrain LFP recordings)]. Quantification of brain recordings of VHC-treated WT larvae [VHC(+/+), n = 42], VHC-treated scn1a mutant larvae [VHC(−/−),
n = 41] and compound-treated scn1a mutant larvae [compound(−/−)]. (A) Frequency of epileptiform events during 10 minutes recording. (B) Mean cumulative
duration of epileptiform events during 10 min recording. Single treatment with FA reduced epileptiform brain activity (n = 50), which was counteracted by
combinatorial treatment with the σ1-agonist (n = 13), the 5-HT1D-antagonist (n = 18) or the 5-HT2C-antagonist (n = 16). A statistical difference is indicated by
∗p < 0.05 and ∗∗∗p < 0.001. (C) Visualization of representative electrograms of 7 dpf ZF larvae: FA-treated scn1a mutant larva [FA(−/−)]; FA-treated scn1a mutant
larva in combination with the σ1-agonist [FA+ σ1-agonist(−/−)] or triple treatment with epileptiform compounds [σ1-agonist+5-HT1D&2C-antagonists (−/−)]; scale
bars: 1 mV, 30 s.
FIGURE 6 | Activity profile of the sigma1-agonist (σ1) and subtype selective 5-HT-antagonists (1D, 2A, 2C, 2B) (locomotor behavioral assays).
Locomotor activity was normalized against VHC-treated scn1a mutant larvae (−/−) and displayed as a percentage ± SD. (A1) Normalized locomotor activity of
treated scn1a mutant larvae (−/−). (A2) Normalized locomotor activity of treated WT larvae (+/+). (B) Percentage of scn1a mutant larvae with epileptiform activity
below (white area) or above the threshold value (black area). Single treatment with the σ1-agonist (σ1) and the subtype selective 5-HT-antagonists (1D, 2A, 2C, 2B)
did not significantly affect the epileptiform locomotor behavior. A statistical difference is indicated by: ∗p < 0.05 vs. VHC-treated controls. n = 20 ZF larvae for all
experimental conditions.
greater extent (58% decrease compared to VHC, Figure 2A1),
which is similar to the decrease elicited by FA (>55% decrease
compared to VHC; Figure 4A1). Subsequent brain recordings
confirmed these anti-epileptiform effects, though no major
differences were observed between single and triple treatment
(Figures 3, 5). Consistently, statistical analyses did not show
any significant differences between triple treatment and single
treatments (p < 0.05).
Counteraction of FA’s Anti-epileptiform
Activity by Sigma1-Agonism and
5-HT1D&2C-Antagonism (Triple Treatment)
Combinatorial treatment of FA with single treatment of the
σ1-agonist, 5-HT1D- or 5-HT2C-antagonist counteracted FA’s
decrease in locomotor activity (range 0–41% increase relative
to FA; Figure 4A1). Triple treatment (combination of the
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FIGURE 7 | Neurotransmitter content in head homogenates of ZF larvae (nmol/mg). Data for each condition were collected from eight samples with each six
heads (n = 48). ∗p < 0.05 and ∗∗p < 0.01 indicate a statistically significant alteration of some neurotransmitters (Supplementary Table S6; Two-way ANOVA).
aforementioned three compounds) counteracted FA’s decrease in
locomotor activity more profoundly (89% increase relative to
FA; Figure 4A1). Consistently, brain recordings confirmed the
counteraction of FA’s anti-epileptiform effect and showed that
triple treatment counteracted FA’s effect more profoundly (116–
144% increase relative to FA for the frequency and cumulative
duration of epileptiform events, respectively; Figure 5), in
comparison to the single treatment counteraction experiments
(74–91% relative to FA for the frequency and cumulative
duration of epileptiform events, respectively; Figure 5). Overall,
these more pronounced counteractive effects by triple treatment
compared to single treatments were not statistically significant
(p > 0.05).
Neurotransmitter Changes after FA
Treatment
Our data indicate an overall reduction of two out of three
monoamines after FA treatment, i.e., DOP and NAD (Figure 7).
The most pronounced and significant decrease was shown for
NAD (Figure 7 and Supplementary Table S6).
The only statistical significant difference between both
genotypes was the GLUT content which was significantly higher
in scn1a mutant larvae (−/−) when compared to WT larvae
(+/+). However, GLUT content was not significantly altered after
FA treatment (Figure 7 and Supplementary Table S6).
DISCUSSION
Dravet syndrome is one of the most drug-resistant forms of
epilepsy that typically starts in the first year of life (Nolan
et al., 2011). Recently, it was shown that the serotonergic
drug FA is a potent add-on AED in DS patients (Ceulemans
et al., 2012). Although this compound shows great promise
for future therapeutic regimens in the treatment of DS
and possibly other drug-resistant epileptic syndromes, it is
presently unknown which 5-HT receptor subtypes are involved
in its action and whether other mechanisms beyond its
serotonergic profile play a part. This situation hampered a full
mechanistic appreciation of the clinical performance of the
compound.
Serotonergic Activity (5-HT)
In previous experimental work using scn1a mutant larvae, which
mimic well the epileptiform features of DS in ZF, we have shown
that selective pharmacological agonists of the 5-HT1D, 5-HT2A
and 5-HT2C receptor subtypes (GR 46611, TCB 2 and lorcaserin,
respectively) substantially decreased the epileptiform activity. Of
importance, stimulation of other 5-HT receptor subtypes was
not met with success. Using an identical approach here, we
explored whether selective antagonists of 5-HT1D, 5-HT2A and 5-
HT2C receptor subtypes were able to counteract the FA-induced
inhibition of epileptiform locomotor and brain activity observed
in scn1a mutant larvae. We show that antagonists of 5-HT1D
and the 5-HT2C receptor subtypes were able to do so (LY 310762
and SB 242084, respectively), but notably, the 5-HT2A-antagonist
(ketanserin) was not.
Of importance, and in line with our previous findings
(Sourbron et al., 2016), a 5-HT2B-antagonist (SB 204741) did
not counteract the anti-epileptiform activity of FA. Consequently,
we can conclude that the 5-HT2B receptor subtype, that is
proven to cause cardiotoxic effects after prolonged use of FA
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(Rothman et al., 2000), is not involved in the anti-epileptiform
effect of FA.
We also examined the anti-epileptiform activity of the subtype
selective 5-HT1D-, 5-HT2A- and 5-HT2C-antagonists without
combinatorial FA treatment (i.e., single treatment) as other
studies have shown that blocking these receptor subtypes can
protect against seizures in other seizure/epilepsy models. For
example, the 5-HT2A-antagonist used in this study, ketanserin,
protected against seizures induced by hippocampal kindling in
cats (Wada et al., 1992). The same antagonist was also involved
in increasing the latency to audiogenic seizures in DBA/2
mice (Semenova and Tiku, 1997). Consistently, the 5-HT2C-
antagonist, mesulergine, inhibited myoclonic jerks induced by
5-HTP in guinea pigs. This latter antagonist primarily blocks the
5-HT2C receptor and displays affinity for the 5-HT2A receptor
subtype (Pappert et al., 1998). Selective pharmacological blockade
of the 5-HT1D receptor also inhibited myoclonic jerks in the same
model of generalized myoclonus (Hagan et al., 1995). However,
our data clearly show that antagonists for these 5-HT receptor
subtypes did not show any anti-epileptiform activity in our ZF
model of DS.
Beta2-Adrenergic Activity (β2)
The activity of FA has always been labeled as 5-HT related,
as confirmed in this study. Nonetheless, recent in vitro data
suggested antagonism of sigma (σ) and beta2-adrenergic (β2)
receptors as part of its pharmacological spectrum (Parthena et al.,
2016). Hence, in this study we used the scn1a mutant larvae to
explore the anti-epileptiform activity of σ- and β2- antagonism in
in vivo conditions.
A selective antagonist of the β2-adrenergic receptor (ICI
118551) was able to significantly reduce the locomotor activity
of scn1a mutant larvae. This is in agreement with the findings
of Luchowska et al. (2001), that showed an anti-epileptiform
effect against maximal electroshock-induced seizures in mice
by antagonizing the β-adrenergic receptor. Additionally,
β-adrenergic receptors have been implicated in audiogenic
seizures and pindolol, a potent β-antagonist, was found to
attenuate audiogenic seizures in DBA/2 mice (Lints and Nyquist-
Battie, 1985). Nevertheless, in this work we show that the
percentage of scn1a mutant larvae with decreased epileptiform
activity was not significantly changed. In addition, the locomotor
activity of WT larvae was decreased, suggesting a non-specific
alteration of locomotor activity (i.e., potential sedative or
muscle-relaxant effect). In line with these latter findings, the
β2-antagonist did not decrease epileptiform brain activity. Thus,
our in vivo data imply that the β2-adrenergic receptor is not
involved in modulating epileptiform activity in the ZF DS
model.
Sigma Activity (σ1 and σ2)
As far as the sigma receptors are concerned, the σ1-antagonist
(NE 100) decreased both epileptiform behavior and especially
brain activity in scn1a mutant larvae. On the other hand, the σ1-
agonist (PRE 084) did not counteract FA’s decrease in abnormal
locomotor activity (behavioral assays, Figure 4), whereas brain
activity recordings clearly demonstrated a statistically significant
counteraction (Figure 5). Locomotion is regulated in a complex
way in different parts of the brain (Dunn et al., 2016) and it is
possible that these neuronal activities are not always consistent
with the brain activity alterations recorded by a single electrode
positioned at the forebrain. Alternatively, it is also conceivable
that the σ1-agonist (PRE 084) does not uniformly distribute over
the brain, and that especially the peripheral areas probed by
the electrode accumulated more compound resulting in a more
pronounced effect.
Altogether, the data therefore suggest an involvement of the σ1
receptor in the mechanism of FA, beyond its serotonergic profile.
In contrast, treatment with the σ2-antagonist (SM 21) did not
reduce epileptiform activity in scn1a mutant larvae. This result
was somewhat anticipated as most studies underline the role of
the σ2 subtype receptor in cancer-related diseases, rather than in
brain-related disorders (Rousseaux and Greene, 2015).
Of interest, a number of studies demonstrate the role of
σ1 receptors in neurological diseases like epilepsy (Rousseaux
and Greene, 2015) and overstimulation of σ1 receptors has
been associated with GLUT-related excitatory effects (via NMDA
receptors) (Borlot et al., 2014; Nicita et al., 2014; Rousseaux
and Greene, 2015). In addition, blockade of σ1 receptors was
associated directly with anti-epileptiform activity (Matsumoto
et al., 2002). In contrast, also σ1-agonists have also been shown
to exert clear anti-seizure effects (Meurs et al., 2007; Guo et al.,
2015), and possibly σ1-agonist/antagonists might exert different
activities depending on the seizure/epilepsy model. Anyhow,
our data show that σ1-agonism was ineffective in reducing
epileptiform events, whereas σ1-antagonism likely plays a role in
the mechanism of FA in the ZF DS model.
Neurotransmitter Content
The neurotransmitter content analysis of scn1a mutants
compared to WT only demonstrated a statistically significant
increase in GLUT (p = 0.0036). This finding is in line with
the neuro-excitatory properties related to GLUT and its role
in epilepsy (Meldrum, 1994). Hence it is not surprising that
decreasing glutamatergic effects is one of the main targets
for currently available AEDs (Landmark, 2007). Nonetheless,
the anti-epileptic compound FA did not alter GLUT levels.
Interestingly, the concentration of other neurotransmitters
(i.e., NAD and DOP) in head homogenates was altered after
FA treatment. Our data indicate a significant DOP decrease
by almost one third compared to the VHC treated group
(p = 0.0335). The NAD content was even nearly halved when
comparing the FA vs. the VHC treated group (p = 0.0035).
The latter result is therefore in line with previous work that
demonstrated a FA-related decrease of the NAD content in rat
brain (Calderini et al., 1975).
As 5-HT-agonism (Astorne Figari et al., 2014) but also
σ-antagonism (Monnet et al., 1992) can result in decreased NAD
signaling, we hypothesize that the reduction of NAD content
after FA treatment as observed in this study is due the effects
of FA at 5-HT2C and σ1 receptors. Of interest, elevated NAD
transmission has been associated with some cases of epilepsy
(Fitzgerald, 2010) and although some studies show contradictory
results (Svob Strac et al., 2016), also evidence exists supporting
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the use of NAD-decreasing drugs in the treatment of neurological
diseases, including epilepsy (Fitzgerald, 2015).
Of importance, the concentrations measured encompass
the total intra- and extracellular levels, so inter-synaptic level
alterations were not assessed.
The following, yet incomplete, hypothesis emerges regarding
the pharmacological profile of FA that underlies the treatment of
DS and possibly other SCN1A-related epilepsies. Of importance,
the present study used only one agonist or antagonist at their
respective MTCs for the exploration of the involvement of some
type of receptors, and further experiments using alternative
methods (e.g., a genetic approach using receptor gene knock-
down or overexpression) are needed to confirm the present
results.
SCN1A mutations, as a major monogenic cause of DS, lead
to a malfunction of the encoded voltage-gated sodium channels
1.1 (Nav1.1). In mammalian (rodent) DS models these channels
are mainly affected in inhibitory (GABAergic) interneurons and
to a lesser extent in excitatory pyramidal neurons (Dutton et al.,
2013; Mistry et al., 2014). As a result, neuronal inhibition is
impaired, which is assumed to cause seizures (Wong et al.,
2016). Our data suggest that FA reduces epileptiform activity
by stimulating 5-HT2C and 5-HT1D receptors, leading to
enhanced GABAergic neurotransmission (as proven for 5-HT2C
receptors) (Shen and Andrade, 1998; Higgins et al., 2014),
and by a σ1-antagonistic action that can reduce the excitatory
neurotransmission by modulating NMDA responses (Rousseaux
and Greene, 2015). In addition, FA also significantly decreases
the NAD brain content that might contribute to its anti-epileptic
effects.
CONCLUSION
This work extends our current understanding of the anti-epileptic
mechanisms of FA, beyond its serotonergic activity. Using an
in vivo scn1a mutant ZF model we demonstrated that the
anti-epileptiform activity of FA not only originates from its 5-
HT1D- and 5-HT2C-agonism, but likely also from its ability to
block σ1 receptors. These findings will help to understand the
pharmacological profile of compounds that is critical for their
applicability in the treatment of DS and possibly also other
drug-resistant epilepsies.
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